Cited by 1,949Cancer-related Molecular PathwaysSarcoma Diagnosis and TreatmentHeat shock proteins research

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Amplification of a gene encoding a p53-associated protein in human sarcomas

Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., Vogelstein, B.·1992·Nature

Open this paper in CoChat — free account

Abstract

Despite extensive data linking mutations in the p53 gene to human tumorigenesis, little is known about the cellular regulators and mediators of p53 function. MDM2 is a strong candidate for one such cellular protein; the MDM2 gene was originally identified by virtue of its amplification in a spontaneously transformed derivative of mouse BALB/c cells and the MDM2 protein subsequently shown to bind to p53 in rat cells transfected with p53 genes. To determine whether MDM2 plays a role in human cancer, we have cloned the human MDM2 gene. Here we show that recombinant-derived human MDM2 protein binds human p53 in vitro, and we use MDM2 clones to localize the human MDM2 gene to chromosome 12q13-14. Because this chromosomal position appears to be altered in many sarcomas, we looked for changes in human MDM2 in such cancers. The gene was amplified in over a third of 47 sarcomas, including common bone and soft tissue forms. These results are consistent with the hypothesis that MDM2 binds to p53, and that amplification of MDM2 in sarcomas leads to escape from p53-regulated growth control. This mechanism of tumorigenesis parallels that for virally-induced tumours, in which viral oncogene products bind to and functionally inactivate p53.

Integrity signals

Registry

Crossref · 10.1038/358080a0

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
Feinberg, A. P., & Vogelstein, B. (1983) · Analytical Biochemistry · doi:10.1016/0003-2697(83)90418-9 · Cited by 24,512
Self-citation
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,524
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Self-citation
A simple and very efficient method for generating cDNA libraries
Gubler, U., & Hoffman, B. J. (1983) · Gene · doi:10.1016/0378-1119(83)90230-5 · Cited by 4,461
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Self-citation
How eukaryotic transcriptional activators work
Ptashne, M. (1988) · Nature · doi:10.1038/335683a0 · Cited by 1,828
Identification of a Chromosome 18q Gene that Is Altered in Colorectal Cancers
Fearon, E. R., Cho, K. R., Nigro, J. M., Kern, S. E., Simons, J. W., Ruppert, J. M., Hamilton, S. R., Preisinger, A. C., Thomas, G., Kinzler, K. W., et al. (1990) · Science · doi:10.1126/science.2294591 · Cited by 1,760
Self-citation
Rapid transfer of DNA from agarose gels to nylon membranes
Reed, K. C., & Mann, D. A. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.20.7207 · Cited by 1,731
Casein kinase 2: An ‘eminence grise’ in cellular regulation?
Pinna, L. A. (1990) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(90)90098-x · Cited by 920

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 4

Hinds, P. W. et al. Cell Growth Differ. 1, 571–580 (1990).
Momand, J., Zambetti, G. P., Olson, D. C., George, D. L. & Levine, A. J. Cell (in the press).
Meltzer, P. S. et al. Cell Growth Differ. 2, 495–501 (1991).
Vogelstein, B. et al. Cancer Res. 47, 4806–4813 (1987).

Sorted by citations

Items 701–800 of 999

p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus
Jeffers, M. D., Farquharson, M. A., Richmond, J. A., & McNicol, A. (1995) · The Journal of Pathology · doi:10.1002/path.1711770111 · Cited by 58
Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop
Arriola, E. L., Lopez, A. R., & Chresta, C. M. (1999) · Oncogene · doi:10.1038/sj.onc.1202391 · Cited by 58
The Tumor Suppressor p53 and the Oncoprotein Simian Virus 40 T Antigen Bind to Overlapping Domains on the MDM2 Protein
Brown, D. R., Deb, S., Muñoz, R. M., Subler, M. A., & Deb, S. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.11.6849 · Cited by 58
Lack ofp53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions
Papp, T., Jafari, M., & Schiffmann, D. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01213550 · Cited by 57
True
Yamamoto, H., Murakami, H., Hosaka, T., Nakamata, T., Oka, M., Toguchida, J., Tsuboyama, T., Nakamura, T., & Nakayama, T. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1213 · Cited by 58
MDM2 Amplification, P53 Mutation, and Accumulation of the P53 Gene Product in Malignant Fibrous Histiocytoma
Reid, A. H., Tsai, M. M., Venzon, D. J., Wright, C. F., Lack, E. E., & O’Leary, T. J. (1996) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199603000-00010 · Cited by 58
Tied Up in Loops: Positive and Negative Autoregulation of p53Preprint
Lü, X. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000984 · Cited by 58
Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification
Cornillie, J., Wozniak, A., Li, H., Gebreyohannes, Y. K., Wellens, J., Hompes, D., Debiec-Rychter, M., Sciot, R., & Schöffski, P. (2020) · Clinical and Translational Oncology · doi:10.1007/s12094-019-02158-z · Cited by 56
MdmX Promotes Bipolar Mitosis To Suppress Transformation and Tumorigenesis in p53-Deficient Cells and Mice
Matijasevic, Z., Steinman, H. A., Hoover, K., & Jones, S. N. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01108-07 · Cited by 58
Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention
Fhu, C. W., & Ali, A. (2021) · Cancers · doi:10.3390/cancers13071513 · Cited by 59
Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers
He, L., Zhong, Z., Chen, M., Liang, Q., Wang, Y., & Tan, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.775084 · Cited by 57
Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres
González, A. Z., Li, Z., Beck, H. P., Canon, J. R., Chen, A., Chow, D. T., Duquette, J., Eksterowicz, J. E., Fox, B. M., Fu, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401911v · Cited by 60
Self-citation
Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
DeVine, T., & Dai, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180009 · Cited by 58
Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma
Dai, L., Ren, P., Liu, M., Imai, H., Tan, E. M., & Zhang, J. Y. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.03.007 · Cited by 58
Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action
Qin, J., Nag, S. A., Voruganti, S., Wang, W., & Zhang, R. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803988910 · Cited by 57
Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction
Chessari, G., Hardcastle, I. R., Ahn, J. S., Anil, B., Anscombe, E., Bawn, R. H., Bevan, L., Blackburn, T. J., Buck, I. M., Cano, C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02188 · Cited by 58
Mdm2: A Regulator of Cell Growth and Death
Alarcon-Vargas, D., Takahashi, S., & Ronai, Z. A. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)01001-7 · Cited by 57
Conditional allele of mdm2 which encodes a p53 inhibitor
Grier, J. D., Yan, W., & Lozano, G. (2002) · genesis · doi:10.1002/gene.10066 · Cited by 57
Synchronous and metachronous lung carcinomas: Molecular evidence for multicentricity
Hiroshima, K., Toyozaki, T., Kohno, H., Ohwada, H., & Fujisawa, T. (1998) · Pathology International · doi:10.1111/j.1440-1827.1998.tb03853.x · Cited by 57
Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma
Momoi, H., Itoh, T., Nozaki, Y., Arima, Y., Okabe, H., Satoh, S., Toda, Y., Sakai, E., Nakagawara, K.-I., Flemming, P., et al. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00106-4 · Cited by 57
P53 tumour suppressor gene and germ cell neoplasia
Lutzker, S. G. (1998) · Apmis · doi:10.1111/j.1699-0463.1998.tb01323.x · Cited by 57
MEK-ERK Signaling Controls Hdm2 Oncoprotein Expression by Regulating hdm2 mRNA Export to the Cytoplasm
Phelps, M., Phillips, A., Darley, M., & Blaydes, J. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412334200 · Cited by 57
p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: A third member of the p53 family?
Bian, J., & Sun, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14753 · Cited by 57
The mdm2 Proto-Oncogene
Haines, D. S. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709051772 · Cited by 58
Infrequent p53 mutations in 7,12‐dimethylbenz[a]anthracene–induced mammary tumors in BALB/c and p53 hemizygous mice
Jerry, D. J., Butel, J. S., Donehower, L. A., Paulson, E. J., Cochran, C., Wiseman, R. W., & Medina, D. (1994) · Molecular Carcinogenesis · doi:10.1002/mc.2940090309 · Cited by 57
Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells.
Meir, E. G. V., Roemer, K., Diserens, A., Kikuchi, T., Rempel, S. A., Haas, M., Huang, H., Friedmann, T., de Tribolet, N., & Cavenee, W. K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.4.1008 · Cited by 57
CYTOGENETICS AND MOLECULAR GENETICS IN MULTIPLE MYELOMA
Feinman, R., Sawyer, J. R., Hardin, J., & Tricot, G. J. K. (1997) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70412-3 · Cited by 57
A comprehensive study of p53 protein
Patil, M. R., & Bihari, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30331 · Cited by 57
Molecular Docking and Molecular Dynamics Studies Reveal the Anticancer Potential of Medicinal-Plant-Derived Lignans as MDM2-P53 Interaction Inhibitors
Shoaib, T. H., Abdelmoniem, N., Mukhtar, R. M., Alqhtani, A. T., Alalawi, A. L., Alawaji, R., Althubyani, M. S., Mohamed, S. G. A., Mohamed, G. A., Ibrahim, S. R. M., et al. (2023) · Molecules · doi:10.3390/molecules28186665 · Cited by 61
Human RAD9 checkpoint control/proapoptotic protein can activate transcription of p21
Yin, Y., Zhu, A., Jin, Y. J., Liu, Y., Zhang, X., Hopkins, K. M., & Lieberman, H. B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403130101 · Cited by 56
p53 ubiquitination by Mdm2: A never ending tail?
Coutts, A. S., Adams, C., & Thangue, N. B. L. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.01.008 · Cited by 56
Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers.
Melhem, M. F., Law, J. C., El-Ashmawy, L., Johnson, J. T., Landreneau, R. J., Srivastava, S., & Whiteside, T. L. (1995) · Europe PMC (PubMed Central) · Cited by 56
MDM2 Mediates p300/CREB-binding Protein-associated Factor Ubiquitination and Degradation
Jin, Y., Zeng, S. X., Lee, H., & Lu, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309916200 · Cited by 56
pRB induces Sp1 activity by relieving inhibition mediated by MDM2
Johnson‐Pais, T. L., Degnin, C., & Thayer, M. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051415898 · Cited by 56
C-Abl as a modulator of p53
Levav-Cohen, Y., Goldberg, Z., Zuckerman, V., Grossman, T., Haupt, S., & Haupt, Y. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.152 · Cited by 57
An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines.
Bae, I. S., Smith, M. L., Sheikh, M. S., Zhan, Q., Scudiero, D. A., Friend, S. H., O'Connor, P. M., & Fornace, A. J. (1996) · PubMed · Cited by 56
Analysis of the p53 and MDM‐2 gene in acute myeloid leukemia
Seliger, B., Papadileris, S., Vogel, D. W., Heß, G., Brendel, C. A., Störkel, S., örtel, J., Kolbe, K., Huber, C. H., Huhn, D., et al. (1996) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1996.tb01369.x · Cited by 56
MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling
Zhang, C., Liu, J., Wang, X., Wu, R., Lin, M., Laddha, S. V., Yang, Q., Chan, C. S., & Feng, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.2379 · Cited by 55
Network-Guided Analysis of Genes with Altered Somatic Copy Number and Gene Expression Reveals Pathways Commonly Perturbed in Metastatic Melanoma
Valsesia, A., Rimoldi, D., Martinet, D., Ibberson, M. R., Benaglio, P., Quadroni, M., Waridel, P., Gaillard, M., Pidoux, M., Rapin, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018369 · Cited by 54
Mdm2 and MdmX as Regulators of Gene Expression
Biderman, L., Manley, J. L., & Prives, C. L. (2012) · Genes & Cancer · doi:10.1177/1947601912455331 · Cited by 58
MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed–Sternberg cells: results from single‐cell polymerase chain reaction and molecular cytogenetic studies
Küpper, M., Joos, S., von Bonin, F., Daus, H., Pfreundschuh, M. G., Lichter, P., & Trümper, L. H. P. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02566.x · Cited by 55
Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells
White, C. A., Thomson, S. A., Cooper, L. T., Endert, P. V., Tampé, R., Coupar, B. E. H., Li, Q., Parsons, P. G., Moss, D. J., & Khanna, R. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980209)75:4 · Cited by 27
Presence of human papillomavirus sequences in tumour-derived human oral keratinocytes expressing mutant p53
Yeudall, W. A., Paterson, I. C., Patel, V., & Prime, S. S. (1995) · European Journal of Cancer Part B Oral Oncology · doi:10.1016/0964-1955(94)00030-8 · Cited by 55
Genetic studies and molecular markers of bladder cancer
Cordon‐Cardo, C., Sheinfeld, J., & Dalbagni, G. M. (1997) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(199709/10)13:5 · Cited by 55
Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas–a possible mechanism for altering the nm23-H1 activity
Forus, A., D'Angelo, A., Henriksen, J. M., Merla, G., Mælandsmo, G. M., Flørenes, V. A., Olivieri, S., Bjerkehagen, B., Meza‐Zepeda, L. A., Blanco, F. D. V., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204874 · Cited by 55
Analysis of p53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry
Koga, H., Zhang, S., Kumanishi, T., Washiyama, K., Ichikawa, T., Tanaka, R., & Mukawa, J. (1994) · Acta Neuropathologica · doi:10.1007/bf00296737 · Cited by 55
MDM2 Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers
Forslund, A., Zeng, Z., Qin, L.-X., Rosenberg, S., Ndubuisi, M., Pincas, H., Gerald, W., Notterman, D. A., Barany, F., & Paty, P. B. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0239 · Cited by 54
The evolution of MDM2 family genes
Momand, J. A., Villegas, A., & Белый, В. А. (2011) · Gene · doi:10.1016/j.gene.2011.06.030 · Cited by 55
MDM2 Binding Induces a Conformational Change in p53 That Is Opposed by Heat-shock Protein 90 and Precedes p53 Proteasomal Degradation
Sasaki, M. M., Nie, L., & Maki, C. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610514200 · Cited by 54
Isoquinolin‐1‐one Inhibitors of the MDM2–p53 Interaction
Rothweiler, U., Czarna, A., Krajewski, M., Ciombor, J., Kalinski, C., Khazak, V., Roß, G., Skobeleva, N., Weber, L., & Holak, T. A. (2008) · ChemMedChem · doi:10.1002/cmdc.200800025 · Cited by 55
Chromosome 12 origin in rings and giant markers in well-differentiated liposarcoma
Pédeutour, F., Suijkerbuijk, R. F., Gaal, J., Klundert, W. V. D., Coindre, J., Haelst, A. V., Collin, F., Huffermann, K., & Turc‐Carel, C. (1993) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(93)90245-h · Cited by 54
The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas
Forus, A., Flørenes, V. A., Mælandsmo, G. M., Fodstad, Ø., & Myklebost, O. (1994) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(94)90085-x · Cited by 54
Regulation of MyoD Activity and Muscle Cell Differentiation by MDM2, pRb, and Sp1
Guo, C. S., Degnin, C., Fiddler, T. A., Stauffer, D. R., & Thayer, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301943200 · Cited by 54
Roles for negative cell regulator 14-3-3σ in control of MDM2 activities
Hy, Y., Yy, W., Yi, L., Pham, L., Su, C.-H., Yang, H., Chen, J., & Lee, M.-H. (2007) · Oncogene · doi:10.1038/sj.onc.1210540 · Cited by 54
Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk
Walsh, C., Miller, C. W., Karlan, B. Y., & Koeffler, H. P. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.10.008 · Cited by 54
FAT 10, a gene up-regulated in various cancers, is cell-cycle regulated
Lim, C.-B., Zhang, D., & Lee, C. G. L. (2006) · Cell Division · doi:10.1186/1747-1028-1-20 · Cited by 54
Soft tissue sarcoma of the extremities. A multimodality diagnostic and therapeutic approach
Ham, S. J., van der Graaf, W. T. A., Pras, E., Molenaar, W. M., van den Berg, E., & Hoekstra, H. J. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90001-9 · Cited by 54
Genetic Alterations in Patients With Esophageal Cancer With Short- and Long-Term Survival Rates After Curative Esophagectomy
Shimada, Y., Imamura, M., Shibagaki, I., Tanaka, H., Miyahara, T., Kato, M., & Ishizaki, K. (1997) · Annals of Surgery · doi:10.1097/00000658-199708000-00007 · Cited by 54
Centrosome Hyperamplification in Head and Neck Squamous Cell Carcinoma: A Potential Phenotypic Marker of Tumor Aggressiveness
Gustafson, L. M., Gleich, L. L., Fukasawa, K., Chadwell, J. B., Miller, M. A., Stambrook, P. J., & Gluckman, J. L. (2000) · The Laryngoscope · doi:10.1097/00005537-200011000-00004 · Cited by 55
Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma:
Forus, A., Larramendy, M. L., Meza‐Zepeda, L. A., Bjerkehagen, B., Godager, L. H., Dahlberg, A. B., Sæter, G., Knuutila, S., & Myklebost, O. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(00)00369-1 · Cited by 54
Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas
Jensen, V., Sørensen, F. B., Bentzen, S. M., Ladekarl, M. B., Nielsen, O. S., Keller, J. O., & Jensen, O. M. (1998) · Histopathology · doi:10.1046/j.1365-2559.1998.00425.x · Cited by 54
Constitutively active DNA damage checkpoint pathways as the driving force for the high frequency of p53 mutations in human cancer
Halazonetis, T. D. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.03.036 · Cited by 53
Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer
de Oliveira, G. A. P., Rangel, L. P., da Costa, D. C. F., & Silva, J. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00097 · Cited by 56
Effects of Δ40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53
Hafsi, H., Santos‐Silva, D., Courtois-Cox, S., & Hainaut, P. L. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-134 · Cited by 56
Gambogic acid down-regulates MDM2 oncogene and induces p21Waf1/CIP1 expression independent of p53
Rong, J., Hu, R., Qi, Q., Gu, H.-Y., Zhao, Q. J., Wang, J., Mu, R., You, Q., & Guo, Q. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.04.011 · Cited by 53
Molecular signature of anastasis for reversal of apoptosis
Tang, H. M., Talbot, C. C., Fung, M. C., & Tang, H. L. (2017) · F1000Research · doi:10.12688/f1000research.10568.2 · Cited by 71
Hepatocellular carcinoma cell cycle: Study of Long-Evans Cinnamon rats
Masaki, T., Shiratori, Y., Rengifo, W., Igarashi, K., Matsumoto, K., Nishioka, M., Hatanaka, Y., & Omata, M. (2000) · Hepatology · doi:10.1053/jhep.2000.17705 · Cited by 53
p53 Expression in Langerhans Cell Histiocytosis
Weintraub, M., Bhatia, K. G., Chandra, R. S., MAGRATH, I. T., & Ladisch, S. (1998) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199801000-00002 · Cited by 53
Different metastatic potentials ofras- andsrc-transformed BALB/c 3T3 A31 variant cells
Tatsuka, M., Ota, T., Yamagishi, N., Kashihara, Y., Wada, M., Matsuda, N., Mitsui, H., Seiki, M., & Odashima, S. (1996) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199604)15:4 · Cited by 26
Self-citation
TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis
Thorlacius, S., Thorgilsson, B., Björnsson, J., Tryggvadóttír, L., Børresen‐Dale, A., Ogmundsdottir, H. M., & Eyfjord, J. E. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00399-4 · Cited by 53
MDM2 Can Promote the Ubiquitination, Nuclear Export, and Degradation of p53 in the Absence of Direct Binding
Inoue, T. M., Geyer, R. K., Howard, D., Yu, Z. K., & Maki, C. G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107477200 · Cited by 54
Human non‐small cell lung cancer: P53 protein accumulation is an early event and persists during metastatic progression
Fontanini, G., Vignati, S., Bigini, D., Basolo, F., Pingitore, R., Bevilacqua, G., Merlo, G. R., Ribechini, A., & Angeletti, C. A. (1994) · The Journal of Pathology · doi:10.1002/path.1711740105 · Cited by 53
Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel‐Lindau tumor suppressor‐binding protein (CUL2 and VBP1) mutation and loss in renal‐cell carcinoma development
Clifford, S. C., Walsh, S., Hewson, K., Green, E., Brinke, A., Green, P. M., Gianelli, F., Eng, C., & Maher, E. R. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199909)26:1 · Cited by 22
The liver‐specific microRNA‐122*, the complementary strand of microRNA‐122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry
Simerzin, A., Zorde‐Khvalevsky, E., Rivkin, M., Adar, R., Zucman‐Rossi, J., Couchy, G., Roskams, T., Govaere, O., Oren, M., Giladi, H., et al. (2016) · Hepatology · doi:10.1002/hep.28679 · Cited by 53
Hereditary Tumor Syndromes and Gliomas
Reuß, D., & von Deimling, A. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-31206-2_5 · Cited by 52
Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: A report from the Children's Oncology Group
Lerman, D. M., Monument, M. J., McIlvaine, E. J., Liu, X., Huang, D., Monovich, L., Beeler, N., Gorlick, R. G., Marina, N. M., Womer, R. B., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25340 · Cited by 55
Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development
Steinman, H. A., Hoover, K. L., Keeler, M. L., Sands, A., & Jones, S. N. (2005) · Oncogene · doi:10.1038/sj.onc.1208930 · Cited by 52
Essential erbB family phosphorylation in osteosarcoma as a target for CI‐1033 inhibition
Hughes, D. P. M., Thomas, D. G., Giordano, T. J., McDonagh, K. T., & Baker, L. H. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20454 · Cited by 53
Analysis of SAS Gene and CDK4 and MDM2 Proteins in Low-Grade Osteosarcoma
Ragazzini, Gamberi, BENASSI, V., Orlando, Sestini, R., Ferrari, C., Molendini, Sollazzo, V., Merli, Magagnoli, G., et al. (1999) · Cancer Detection and Prevention · doi:10.1046/j.1525-1500.1999.09907.x · Cited by 52
Analysis of 12q13-15 Genes in Parosteal Osteosarcoma
Gamberi, G., Ragazzini, P., Benassi, M. S., Ferrari, C., Sollazzo, M. R., Molendini, L., Merli, M., Magagnoli, G., Ruggieri, P., Balladelli, A., et al. (2000) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200008000-00026 · Cited by 52
The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome
Caligiuri, M. A., Strout, M. P., Oberkircher, A. R., Yu, F., de la Chapelle, A., & Bloomfield, C. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3899 · Cited by 52
Multiple Patterns of MDM-2 Deregulation in Human Leukemias: Implications in Leukemogenesis and Prognosis
Bueso-Ramos, C., Manshouri, T., Haidar, M. A., Huh, Y. O., Keating, M. J., & Albitar, M. X. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509051698 · Cited by 52
Differential Activation of p53 Targets in Cells Treated with Ultraviolet Radiation That Undergo Both Apoptosis and Growth Arrest
Reinke, V., & Lozano, G. (1997) · Radiation Research · doi:10.2307/3579567 · Cited by 52
p53 and Ha-ras mutations in chemically induced hamster buccal pouch carcinomas
Chang, K., Lin, S., Koos, S., Pather, K., & Solt, D. B. (1996) · Carcinogenesis · doi:10.1093/carcin/17.3.595 · Cited by 52
Wild‐type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells.
Wu, Y., Liu, Y., Lee, L., Miner, Z., & Kulesz-Martin, M. F. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06808.x · Cited by 53
p53 expression and mutations in squamous cell carcinoma of the head and neck: expression correlates with the patients' use of tobacco and alcohol.
Field, J. K., Zoumpourlis, V., Spandidos, D. A., & Jones, A. S. (1994) · PubMed · Cited by 52
Role of Mdm4 in drug sensitivity of breast cancer cells
Lam, S., Lodder, K., Teunisse, A. F. A. S., Rabelink, M. J. W. E., Schutte, M., & Jochemsen, A. G. (2010) · Oncogene · doi:10.1038/onc.2009.522 · Cited by 52
Corosolic acid sensitizes ferroptosis by upregulating HERPUD1 in liver cancer cells
Peng, Y., Li, N., Tang, F., Qian, C., Jia, T., Liu, J., & Xu, Y. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01169-0 · Cited by 49
MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis
Wan, Y., Wu, W., Yin, Z., Guan, P., & Zhou, B. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-208 · Cited by 52
Potent antiproliferative effects of resveratrol on human osteosarcoma SJSA1 cells: novel cellular mechanisms involving the ERKs/p53 cascade
Alkhalaf, M., & Jaffal, S. M. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.04.019 · Cited by 51
Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators
Lotfy, G., Aziz, Y. M. A., Said, M. M., Ashry, E. S. H. E., Tamany, E. S. H. E., Abu-Serie, M. M., Teleb, M., Dömling, A. S. S., & Barakat, A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105427 · Cited by 50
Clinicopathologiclmplications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors
Yokoyama, R., Schneider‐Stock, R., Radig, K., Wex, T., & Roessner, A. (1998) · Pathology - Research and Practice · doi:10.1016/s0344-0338(98)80096-4 · Cited by 51
p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma
Moch, H., Sauter, G., Gasser, T. C., Buchholz, N., Bubendorf, L., Richter, J., Jiang, F., Dellas, A., & Mihatsch, M. J. (1997) · Urological Research · doi:10.1007/bf00942044 · Cited by 51
Cell cycle alterations and lung cancer.
Vincenzi, B., Schiavon, G., Silletta, M., Santini, D., Perrone, G., Marino, M. D., Angeletti, S., Baldi, A., & Tonini, G. (2006) · PubMed · doi:10.14670/hh-21.423 · Cited by 51
Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas.
Ittmann, M., Wieczorek, R. L., Heller, P., Dave, A., Provet, J. A., & Krolewski, J. J. (1994) · PubMed Central · Cited by 51
bcl‐2 protein expression is associated with better prognosis in colorectal cancer
Leahy, Mulcahy, H. E., O'Donoghue, & Parfrey (1999) · Histopathology · doi:10.1046/j.1365-2559.1999.00743.x · Cited by 51
New insights into p53 protein stabilisation in oral squamous cell carcinoma
Partridge, M., Kiguwa, S., Emilion, G., Pateromichelakis, S., A’Hern, R., & Langdon, J. (1999) · Oral Oncology · doi:10.1016/s1368-8375(98)00051-7 · Cited by 51
Retroviruses and Their Role in Cancer
Fan, H. (1994) · Springer eBooks · doi:10.1007/978-1-4899-1730-0_7 · Cited by 50
The MDM2 RING Domain and Central Acidic Domain Play Distinct Roles in MDM2 Protein Homodimerization and MDM2-MDMX Protein Heterodimerization
Leslie, P. L., Ke, H., & Zhang, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.644435 · Cited by 50
Organocatalytic, Diastereo- and Enantioselective Synthesis of Nonsymmetric cis -Stilbene Diamines: A Platform for the Preparation of Single-Enantiomer cis -Imidazolines for Protein–Protein Inhibition
Vara, B., Mayasundari, A., Tellis, J. C., Danneman, M. W., Arredondo, V., Davis, T. A., Min, J., Finch, K. E., Guy, R. K., & Johnston, J. N. (2014) · The Journal of Organic Chemistry · doi:10.1021/jo501003r · Cited by 50

Authors: Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B.
Affiliations: University of Michigan (US)
Johns Hopkins University (US)
University of Pennsylvania (US)
ORCID: Oliner, J. D.
Kinzler, K. W.
Meltzer, P. S.
George, D. L.
Vogelstein, B.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1992-07
Volume: 358
Issue: 6381
Pages: 80-83
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/358080a0
OpenAlex: W2091151265
Cited by: 1,949
References: 32
Citations by year: 2026: 14 · 2025: 22 · 2024: 23 · 2023: 27 · 2022: 25 · 2021: 36 · 2020: 37 · 2019: 32 · 2018: 20 · 2017: 37 · 2016: 52 · 2015: 46 · 2014: 63 · 2013: 46 · 2012: 58
FWCI: 52.87
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Deep Blue (University of Michigan) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: MDM2, p53, gene amplification, sarcoma, p53 binding, tumor suppressor inactivation, bone sarcoma, soft tissue sarcoma, viral oncogenes, carcinogenesis
MeSH terms: Amino Acid Sequence, Base Sequence, Chromosomes, Human, Pair 12, Cloning, Molecular, DNA, Gene Amplification, Humans, Molecular Sequence Data, Neoplasm Proteins, Neoplasms, Nuclear Proteins, Proto-Oncogene Proteins, RNA, Messenger, RNA, Neoplasm, Sequence Homology, Nucleic Acid, Gene Expression, Tumor Suppressor Protein p53, Sequence Alignment, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amplification of a gene encoding a p53-associated protein in human sarcomas

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks